Other Clinical Trial - Reducing Antibiotic Prescribing in Family Practice

Status Not yet recruiting

Clinical Trial Summary

Antibiotic prescribing for childhood acute respiratory tract infections (ARTIs), including acute otitis media (AOM), pharyngitis, sinusitis, bronchitis, and upper respiratory infection (URI), is common in the United States (US). In the outpatient setting, more than 50% of children diagnosed with ARTIs receive antibiotic prescriptions. Considering that the estimated US prevalence of pediatric bacterial ARTIs is 27% (with the remainder of ARTIs caused by viruses) this represents a substantial degree of antibiotic overuse nationwide. Another troubling trend in antibiotic prescribing for ARTIs in children is the increased reliance on broad-spectrum, second-line agents for bacterial ARTIs. Unwarranted use of antibiotics, especially broad-spectrum agents, has been associated with increased resistance among several strains of bacteria that commonly cause ARTIs, posing risks to both individuals and communities.

Clinical Trial Description

Provider-parent communication during ARTI visits often drives unwarranted antibiotic prescribing. Dr. Mangione-Smith (proposed principal investigator) and colleagues developed a quality improvement (QI) intervention for pediatric providers called the Dialogue Around Respiratory Illness Treatment (DART) program. The DART QI program is a multifaceted, web-based intervention that is delivered asynchronously over a 9-month period and takes a total of 2 hours to complete. DART's content is based on over a decade of observational research conducted by Mangione-Smith et al focused on optimizing provider-parent communication during pediatric ARTI visits in order to reduce unnecessary antibiotic prescribing while still maintaining parent satisfaction with care.[cites] The DART program also includes content related to evidence-based antibiotic prescribing with a particular focus on reducing the use of second-line, broad-spectrum antibiotics for bacterial ARTIs.

Under funding from the Eunice Kennedy National Institute for Child Health and Human Development (NICHD), the investigators recently conducted a trial of the DART QI program with 55 providers from 20 practices belonging to one of two pediatric practice-based research networks: the Pediatric Research in Office Settings (PROS) and NorthShore University Health System networks. Exposure to the DART QI program resulted in an proportional decrease from for overall antibiotic prescribing rates for ARTIs and a proportional decrease from for the use of second-line antibiotics for bacterial ARTIs comparing the baseline to the post-intervention periods.

The DART QI Program represents a new, innovative tool to address antibiotic over-use for ARTIs in the pediatric outpatient setting. However, it is unclear whether the program will be effective when disseminated to the family practice clinical setting where 23% of children receive their acute illness care nationally. It is also unclear how exposure to the communication strategies outlined in the DART QI program may influence provider-patient communication during adult encounters for ARTI. ;

Study Design

Related Conditions & MeSH terms

Acute Respiratory Tract Infection
Respiratory Tract Infections

Clinical Trial Details

NCT number	NCT03674775
Study type	Interventional
Source	Seattle Children's Hospital
Contact	Rita Mangione-Smith, MD, MPH
Phone	206-884-8242
Email	Rita.Mangione-Smith@seattlechildrens.org
Status	Not yet recruiting
Phase	N/A
Start date	July 2022
Completion date	June 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04476680` - Influence of Military Preventive Policy for reCruit Training on COVID-19 Seroconversion	N/A
Active, not recruiting	`NCT05127161` - Broad Implementation of Outpatient Stewardship	N/A
Completed	`NCT04579640` - Trial of Vitamin D to Reduce Risk and Severity of COVID-19 and Other Acute Respiratory Infections	Phase 3
Completed	`NCT00981994` - Evaluation of an Algorithm to Reduce Antibiotic Prescribing for Acute Bronchitis	N/A
Completed	`NCT01133782` - Clinical Application of PCR-based Diagnosis of Community-onset Viral Respiratory Infections.	N/A
Completed	`NCT04663776` - Wide Scale Monitoring for Acute Respiratory Infection Using a Mobile-Based Study Platform
Suspended	`NCT05175612` - Differentiation of Upper and Lower Respiratory Tract Infections Using Automated Lung Sound Analysis With LungPass Device
Recruiting	`NCT06278324` - Effectiveness of a Nasal Spray on Viral Respiratory Infections	N/A
Completed	`NCT03379194` - Routine Antibiotic Prescription Monitoring in Primary Care Physicians: A Nationwide Trial	N/A
Withdrawn	`NCT04216277` - The Procalcitonin Guided Antibiotics in Respiratory Infections in General Practice	N/A
Not yet recruiting	`NCT06282718` - A Long-term Observational Study Evaluating the Presentation and Management of Acute Respiratory Tract Infections in Primary Care Across Europe
Completed	`NCT00272116` - Effect of Zinc and Vitamin A Supplementation on Diarrhea, Physical Growth and Immune Response in Malnourished Children	N/A
Completed	`NCT04346693` - An Open Randomized Study of Dalargin Efectiveness in Combination With Leitragin Drug in Patients With Severe and Critical Manifestations of SARS-COVID-19	Phase 3
Not yet recruiting	`NCT05814237` - POS-ARI-ER Observational Study of Acute Respiratory Infections
Completed	`NCT05090475` - Implementation of Academic Detailing Interventions on Prescribing of Antimicrobial Drugs in Primary Health Care	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.